Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption

International Journal of STD and AIDS

Volumn 23, Issue 2, 2012, Pages 120-125

  Kalmar, E M N ^a,b   Sanabani, S S ^c,d   Charlys da Costa, A ^d   Ferreira, S ^c   Barreto, C C ^c   Chen, S ^e   Sabino, E C ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STD/AIDS Reference and Training Center   (Brazil)

^c FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; HIV; Human immunodeficiency virus; Resistance; Treatment interruption

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; DNA SEQUENCE; DRUG WITHDRAWAL; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; PARAMETERS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROVIRUS; TOXICITY; TREATMENT DURATION; TREATMENT INTERRUPTION; VIRUS LOAD; VIRUS TRANSMISSION; WILD TYPE;

ADULT; ANTI-RETROVIRAL AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; VIRAL LOAD;

EID: 84863231116     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.011124     Document Type: Article

References (36)

1. Marins JR, Jamal LF, Chen SY, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-82
2. Nunn AS, Fonseca EM, Bastos FI, et al. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med 2007;4:e305
3. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-83
4. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001;15:2109-17
5. Pires IL, Soares MA, Speranza FA, et al. Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J Clin Microbiol 2004;42:426-30
6. Brindeiro R, Vanderborght B, Caride E, et al. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrob Agents Chemother 1999;43:1674-80
7. Soares MA, De Oliveira T, Brindeiro RM, et al. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 2003;17:11-21
8. Barreto CC, Nishyia A, Araujo LV, et al. Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 2006;41:338-41
9. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-33
10. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-67
11. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80
12. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001;15:185-94
13. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003;37:1541-48
14. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
15. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006;368:459-65
16. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006;367:1981-89
17. Brindeiro RM, Diaz RS, Sabino EC, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 2003;17:1063-69
18. Tanuri A, Caridea E, Dantas MC, et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002;25:39-46
19. Shafer RW, Jung DR, Betts BJ. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med 2000;6:1290-92
20. Bi X, Gatanaga H, Ida S, et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003;34:1-6
21. Kaye S, Comber E, Tenant-Flowers M, Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses 1995;11:1221-25
22. Paolucci S, Baldanti F, Campanini G, et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001;65:207-17
23. Turriziani O, Bucci M, Stano A, et al. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007;44:518-24
24. Chew CB, Potter SJ, Wang B, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005;33:206-16
25. Sarmati L, Nicastri E, Uccella I, et al. Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 2003;41:1760-62
26. Devereux HL, Loveday C, Youle M, et al. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses 2000;16:1025-30
27. Parisi SG, Boldrin C, Cruciani M, et al. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol 2007;45:1783-88
28. Eyer-Silva WA, Couto-Fernandez JC, Silva-de-Jesus C, Morgado MG. Prevalence of HIV type 1 drug resistance mutations in treatment-naive and experienced patients from resource-limited settings with universal access to antiretroviral therapy: a survey in two small Brazilian cities. Mem Inst Oswaldo Cruz 2008;103:143-49
29. Deeks SG. The risk of treatment versus the risk of HIV replication. Lancet 2006;367:1955-56
30. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997;71:1089-96
31. Zennou V, Mammano F, Paulous S, et al. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998;72:3300-06
32. Devereux HL, Loveday C, Youle M, et al. Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. J Infect Dis 2000;181:1804-07
33. Verhofstede C, Wanzeele FV, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-46
34. Trignetti M, Sing T, Svicher V, et al. Dynamics of NRTI resistance mutations during therapy interruption. AIDS Res Hum Retroviruses 2009;25:57-64
35. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20:159-70
36. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82:5510-18